Towards HIV-1 vaccine: Lessons from studies in macaque models

Vaccine

Volumn 16, Issue 9-10, 1998, Pages 904-915

  Hulskotte, Ellen G J ^a   Geretti, Anna Maria ^a,b   Osterhaus, Albert D M E ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^b ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

HIV 1; SHIV; SIV; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 VACCINE; LIVE VACCINE; UNCLASSIFIED DRUG; VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENUATION; DISEASE CONTROL; DISEASE COURSE; DRUG EFFICACY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VIRUS IMMUNITY;

AIDS VACCINES; ANIMALS; DISEASE MODELS, ANIMAL; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION, PASSIVE; MACACA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, ATTENUATED; VACCINES, DNA; VACCINES, INACTIVATED; VACCINES, SYNTHETIC;

EID: 0032078676     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00292-2     Document Type: Article

References (159)

1. 1 World Health Organization, United Nations Children's Fund. Key vaccines under development. In: State of the World's Vaccines and Immunization. World Health Organization, Geneva, 1996, pp. 101-138.
2. 2 Perelson, A.S., Essunger, P. and Cao, Y. et al. Decay characteristics of HIV-1-infected compartments during combination therapy. Nature 1997, 387, 188-191.
3. 3 Schultz, A.M. and Hu, S.L. Primate models for HIV vaccines. AIDS 1993, 7, S161-S170.
4. 4 Gardner, M.B. and Luciw, P.A. Animal models of AIDS. FASEB J. 1989, 3, 2593-2606.
5. 5 Otten, R.A., Brown, B.G. and Simon, M. et al. Differential replication and pathogenic effects of HIV-1 and HIV-2 in Macaca nemestrina. AIDS 1994, 8, 297-306.
6. 6 Frumkin, L.R., Agy, M.B. and Coombs, R.W. et al. Acute infection of Macaca nemestrina by human immunodeficiency virus type 1. Virology 1993, 195, 422-431.
7. 7 Desrosiers, R.C. The simian immunodeficiency viruses. Annu. Rev. Immunol. 1990, 8, 557-578.
8. 8 Clapham, P.R., Blanc, D. and Weiss, R.A. Specific cell surface requirements for the infection of CD4-positive cells by human immunodeficiency virus types 1 and 2 and by Simian immunodeficiency virus. Virology 1991, 181, 703-715.
9. 9 Chen, Z., Zhou, P., Ho, D.D., Landau, N.R. and Marx, P.A. Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J. Virol. 1997, 71, 2705-2714.
10. 10 Choe, H., Farzan, M. and Sun, Y. et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 85, 1135-1148.
11. 11 Norley, S. and Kurth, R. Simian immunodeficiency virus as a model of HIV pathogenesis. Springer Seminars in Immunopathology 1997, 18, 391-405.
12. 12 van der Ende, M.E., Schutten, M., Ly, T.D., Gruters, R.A. and Osterhaus, A.D. HIV-2 infection in 12 European residents: virus characteristics and disease progression. AIDS 1996, 10, 1649-1655.
13. 13 Marlink, R., Kanki, P. and Thior, I. et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994, 265, 1587-1590.
14. 14 Putkonen, P., Bottiger, B., Warstedt, K., Thorstensson, R., Albert, J. and Biberfeld, G. Experimental infection of cynomolgus monkeys (Macaca fascicularis) with HIV-2. J. AIDS 1989, 2, 366-373.
15. 15 Reimann, K.A., Li, J.T. and Veazey, R. et al. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 1996, 70, 6922-6928.
16. 16 Joag, S.V., Li, Z. and Foresman, L. et al. Chimeric simian/ human immunodeficiency virus that causes progressive loss of CD4+ T cells and AIDS in pig-tailed macaques. J. Virol. 1996, 70, 3189-3197.
17. 17 Li, J.T., Halloran, M. and Lord, C.I. et al. Persistent infection of macaques with simian-human immunodeficiency viruses. J. Virol. 1995, 69, 7061-7067.
18. 18 Luciw, P.A., Pratt-Lowe, E., Shaw, K.E., Levy, J.A. and Cheng-Mayer, C. Persistent infection of rhesus macaques with T-cell-line-tropic and macrophage-tropic clones of simian/human immunodeficiency viruses (SHIV). Proc. Natl Acad. Sci. USA 1995, 92, 7490-7494.
19. 19 Igarashi, T., Shibata, R. and Hasebe, F. et al. Persistent infection with SIVmac chimeric virus having tat, rev, vpu, env and nef of HIV type 1 in macaque monkeys. AIDS Res. Hum. Retrovir. 1994, 10, 1021-1029.
20. 20 Ranjbar, S., Jones, S., Stott, E.J. and Almond. N. The construction and evaluation of SIV/HIV chimeras that express the envelope of European HIV Type 1 isolates. AIDS Res. Hum. Retrovir. 1997, 13, 797-800.
21. 21 Mooij, P., Van der Kolk, M., Groenestein, R., Bogers, W., Dubbes, R., Koornstra, W., Ten Haaft, P., Verstrepen, B., Van der Meide, P., Von Hoegen, P., Voss, G., Bruck, C., Almond, N., Stott, J. and Heeney, J. HIV-1. Abstract on EC-CA workshop on FIV, SIV and SHIV Vaccination. Vanney, France, 1997, p. 73.
22. 22 Karlsson, G.B., Halloran, M. and Li, J. et al. Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys. J. Virol. 1997, 71, 4218-4225.
23. 23 Bryson, Y.J., Pang, S., Wei, L.S., Dickover, R., Diagne, A. and Chen, I.S. Clearance of HIV infection in a perinatally infected infant. New Engl. J. Med. 1995, 332, 833-838.
24. 24 Rowland-Jones, S., Sutton, J. and Ariyoshi, K. et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nature Med. 1995, 1, 59-64.
25. 25 Pantaleo, G., Menzo, S. and Vaccarezza, M. et al. Studies in subjects with long-term nonprogressive human immunodeficiency virus infection. New Engl. J. Med. 1995, 332, 209-216.
26. 26 Buchbinder, S.P., Katz, M.H., Hessol, N.A., O'Malley, P.M. and Holmberg, S.D. Long-term HIV-1 infection without immunologic progression. AIDS 1994, 8, 1123-1128.
27. 27 Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M. and Markowitz, M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373, 123-126.
28. 28 Wei, X., Ghosh, S.K. and Taylor, M.E. et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373, 117-122.
29. 29 Mellors, J.W., Rinaldo, C.R. Jr.Jr., Gupta, P., White, R.M., Todd, J.A. and Kingsley, L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272, 1167-1170.
30. 30 Mescher, M.F. Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes. Immunol. Rev. 1995, 146, 177-210.
31. 31 DeGruttola, V., Seage, G.R., Mayer, K.H. and Horsburgh, C.R. Infectiousness of HIV between male homosexual partners. J. Clin. Epidemiol. 1989, 42, 849-856.
32. 32 Oxford, J.S. and Jeffs, S.A. New scientific developments towards an AIDS vaccine: report on a workshop organized by EU programme EVA entitled Novel approaches to AIDS vaccine development held at the Institut Pasteur, Paris. 16-17 November 1995. Vaccine 1996, 14, 1712-1717.
33. 33 Emini, E.A., Schleif, W.A. and Nunberg, J.H. et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 specific monoclonal antibody. Nature 1992, 355, 728-730
34. 34 Prince, A.M., Reesink, H. and Pascual, D. et al. Prevention of HIV infection by passive immunization with HIV immunoglobulin. AIDS Res. Hum. Retrovir. 1991, 7, 971-973.
35. 35 Putkonen, P., Thorstensson, R. and Ghavamzadeh, L. et al. Prevention of HIV-2 and SIVsm infection by passive immunisation in cynomolgus monkeys. Nature 1991, 352, 436-438.
36. 36 Lewis, M.G., Elkins, W.R. and McCutchan, F.E. et al. Passively transferred antibodies directed against conserved regions of SIV envelope protect macaques from SIV infection. Vaccine 1993, 11, 1347-1355.
37. 37 Haigwood, N.L., Watson, A. and Sutton, W.F. et al. Passive immune globulin therapy in the SIV/macaque model: early intervention can alter disease profile. Immunol. Letts 1996, 51, 107-114.
38. 38 Gardner, M., Rosenthal, A., Jennings, M., Yee, J., Antipa, L. and Robinson, E. Jr.Jr. Passive immunization of rhesus macaques against SIV infection and disease. AIDS Res. Hum. Retrovir. 1995, 11, 843-854.
39. 39 Kent, K.A., Kitchin P. and Mills, K.H. et al. Passive immunization of cynomolgus macaques with immune sera or a pool of neutralizing monoclonal antibodies failed to protect against challenge with SIVmac251. AIDS Res. Hum. Retrovir. 1994, 10, 189-194.
40. 40 Gardner, M.B., Rosenthal, A., Jennings, M., Yee, J.A., Antipa, L. and MacKenzie, M. Passive immunization of macaques against SIV infection. J. Med. Primatol. 1994, 23, 164-174.
41. 41 Robinson, J.R., Torres, J.V. and Gardner, M. Antibodies to amino acid 603-622 of simian immunodeficiency (SIV) transmembrane glycoprotein apparently enhance SIV infection in rhesus macaques. In: First National Conference on Human Retroviruses and Related Infections, Washington, DC, December, 1993, p. 79.
42. 42 Mitchell, W.M., Torres, J. and Johnson, P.R. et al. Antibodies to the putative SIV infection-enhancing domain diminish beneficial effects of an SIV gp160 vaccine in rhesus macaques. AIDS 1995, 9, 27-34.
43. 43 Mackewicz, C. and Levy, J.A. CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res. Hum. Retrovir. 1992, 8, 1039-1050.
44. 44 D'Souza, M.P. and Harden, V.A. Chemokines and HIV-1 second receptors. Confluence of two fields generates optimism in AIDS research. Nature Med. 1996, 2, 1293-1300.
45. 45 Baier, M., Werner, A., Bannert, N., Metzner, K. and Kurth, R. HIV suppression by interleukin-16. Nature 1995, 378, 563
46. 46 Clerici, M., Balotta, C. and Meroni, L. et al. Type 1 cytokine production and low prevalence of viral isolation correlate with long-term nonprogression in HIV infection. AIDS Res. Hum. Retrovir. 1996, 12, 1053-1061.
47. 47 Murphy, B.D. and Chanock, R.M. Immunization against virus disease. In: Virology (Eds Fields, B.N., Knipe, D.M. and Howley, P.M.). Lippincott-Raven, Philadelphia, 1996, pp. 467-498.
48. 48 Warren, J.T. and Dolatshahi, M. First updated and revised survey of worldwide HIV and SIV vaccine challenge studies in nonhuman primates: progress in first and second order studies. J. Med. Primatol. 1993, 22, 203-235.
49. 49 Cranage, M.P., Baskerville, A. and Ashworth, L.A. et al. Intrarectal challenge of macaques vaccinated with formalin-inactivated simian immunodeficiency virus. Lancet 1992, 339, 273-274.
50. 50 Marx, P.A., Compans, R.W. and Gettie, A. et al. Protection against vaginal SIV transmission with microencapsulated vaccine. Science 1993, 260, 1323-1327.
51. 51 Johnson, P.R., Montefiori, D.C. and Goldstein, S. et al. Inactivated whole SIV vaccine in macaques: evaluation of protective efficacy against challenge with cell-free virus or infected cells. AIDS Res. Hum. Retrovir. 1992, 8, 1501-1505.
52. 52 Cranage, M., Polanskaya, N. and McBride, B. et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 1993, 9, 13-22.
53. 53 Stott, E.J. Anti-cell antibody in macaques. Nature 1991, 186, 588-596.
54. 54 Arthur, L.O., Bess, J.W. Jr.Jr. and Urban, R.G. et al. Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. J. Virol. 1995, 69, 3117-3124.
55. 55 Chan, W.L., Rodgers, A. and Grief, C. et al. Immunization with class I human histocompatibility leukocyte antigen can protect macaques against challenge infection with SIVmac32H. AIDS 1995, 9, 223-228.
56. 56 Panicali, D.L., Mazzara, G. and Sullivan, J.L. et al. Use of lentivirus-like particles alone and in combination with live vaccinia-virus-based vaccines. AIDS Res. Hum. Retrovir. 1992, 8, 1449
57. 57 Rovinski, B., Haynes, J.R. and Cao, S.X. et al. Expression and characterization of genetically engineered human immunodeficiency virus-like particles containing modified envelope glycoproteins: implications for development of a cross-protective AIDS vaccine. J. Virol. 1992, 66, 4003-4012.
58. 58 Wagner, R., Deml, L. and Notka, F. et al. Safety and immunogenicity of recombinant human immunodeficiency virus-like particles in rodents and rhesus macaques. Intervirology 1996, 39, 93-103.
59. 59 Daniel, M.D., Mazzara, G.P. and Simon, M.A. et al. High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retrovir. 1994, 10, 839-851.
60. 60 Luke, W., Coulibaly, C. and Dittmer, U. et al. Simian immunodeficiency virus (SIV) gp130 oligomers protect rhesus macaques (Macaca mulatta) against the infection with SIVmac32H grown on T-cells or derived ex vivo. Virology 1996, 216, 444-450.
61. 61 Israel, Z., Ednonson, P.F. and Maul, D.H. et al. Incomplete protection but suppression of virus burden elicited by subunit simian immunodeficiency virus vaccines. J. Virol. 1994, 68, 1843-1853.
62. 62 Ahmad, S., Lohman, B. and Marthas, M. et al. Reduced virus load in rhesus macaques immunized with recombinant gp160 and challenged with simian immunodeficiency virus. AIDS Res. Hum. Retrovir. 1994, 10, 195-204.
63. 63 Mossman, S.P., Bex, F. and Berglund, P. et al. Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine. J. Virol. 1996, 70, 1953-1960.
64. 64 Zolla-Pazner, S. Mechanisms contributing to the neutralization of HIV-1. Immunol. Lett. 1996, 51, 89-93.
65. 65 Wyand, M.S., Manson, K.H., Garcia-Moll, M., Montefiori, D. and Desrosiers, R.C. Vaccine protection by a triple deletion mutant of simian immunodeficiency virus. J. Virol. 1996, 70, 3724-3733.
66. 66 Cole, K.S., Rowles, J.L. and Jagerski, B.A. et al. Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity. J. Virol. 1997, 71, 5069-5079.
67. 67 Van Binnendijk, R.S., Van Baalen, C.A. and Poelen, M.C.M. ef al. Measles virus transmembrane fusion protein synthesized de novo or presented in iscoms is endogenously processed for HLA class I and class II-restricted cytotoxic T cell recognition. J. Exp. Med. 1992, 176, 119-128.
68. 68 Takahashi, H., Takeshita, T., Morein, B., Putney, S., Germain, R.N. and Berzofsky, J.A. Induction of CD8+ cytotoxic T cells by immunization with purified HIV-1 envelope protein in iscoms. Nature 1990, 344, 873-875.
69. 69 Putkonen, P., Bjorling, E. and Akerblom, L. et al. Long-standing protection of macaques against cell-free HIV-2 with a HIV-2 iscom vaccine. J. AIDS 1994, 7, 551-559.
70. 70 Nilsson, C., Thortstensson, R. and Gilljam, G. et al. Protection against monkey-cell grwon cell-free HIV-2 challenge in macaques immunized with native HIV-2 envelope glycoprotein gp125. Vaccine Res. 1996, 4, 165-175.
71. 71 De Vries, P., Heeney, J.L. and Boes, J. et al. Protection of rhesus macaques from SIV infection by immunization with different experimental SIV vaccines. Vaccine 1994, 12, 1443-1452.
72. 72 Osterhaus, A.D.M.E., De Vries, P. and Heeney, J. AIDS vaccine developments. Nature 1992, 355, 684-685.
73. 73 Heeney, J.L., Van Els, C.A.C.M, and De Vries, P. et al. Major histocompatibility complex class I-associated vaccine protection from Simian Immunodeficiency Virus infected peripheral blood cells. J. Exp. Med. 1994, 180, 769-774.
74. 74 Hulskotte, E.G.J., Geretti, A.M. and Siebelink, K.H.J. et al. Vaccine-induced virus neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H(J5). J. Virol. 1995, 69, 6289-6296.
75. 75 Hulskotte, E.G.J., Geretti, A.M., Dings, M.E.M., Van Amerongen, G., Mallet, F., Gruters, R.A. and Osterhaus, A.D.M.E. Immunization of cynomologus macaques with envelope glycoproteins from primary HIV-1 isolates induces limited protection against intravenous SHIV challenge. Submitted 1997.
76. 76 Van Gils, M.E., Teeuwsen, V.J.P., Bogers, W.M.J.M., Morein, B., Davis, D., Akerblom, L., De Giuli Morghen, C., Ghioni, C., Gimelli, M., Raddaelli, A. and Heeney, J.L. Immune correlates of HIV-1 vaccine efficacy from heterologous SHIV challenge: Th1 or Th2. In: Abstracts of the EC-CA Workshop on FIV, SIV and SHIV Vaccination, Annecy, France, 1997, p. 35.
77. 77 Lehner, T., Wang, Y. and Cranage, M. et al. Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nature Med. 1996, 2, 767-775.
78. 78 Daniel, M.D., Kirchhoff, F., Czafak, S.C., Sehgal, P.K. and Desrosiers, R.C. Protective effect of a live attenuated SIV vaccine with deletion in nef gene. Science 1992, 258, 1938-1941.
79. 79 Almond, N., Kent, K., Cranage, M., Rud, E., Clarke, B. and Stott, E.J. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 1995, 345, 1342-1344.
80. 80 Clements, J.E., Montelaro, R.C. and Zink, M.C. et al. Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus. J. Virol. 1995, 69, 2737-2744.
81. 81 Yu, X.F., Matsuda, M., Essex, M. and Lee, T.H. Open reading frame vpr of simian immunodeficiency virus encodes a virion-associated protein. J. Virol. 1990, 64, 5688-5693.
82. 82 Cranage, M.P., Whatmore, A.M. and Sharpe, S.A. et al. Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997, 229, 143-154.
83. 83 Otsyula, M.G., Miller, C.J. and Tarantal, A.F. et al. Fetal or neonatal infection with attenuated simian immunodeficiency virus results in protective immunity against oral challenge with pathogenic SIVmac251. Virology 1996, 222, 275-278.
84. 84 Stahl-Hennig, C., Dittmer, U. and Nisslein, T. et al. Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J. Gen. Virol. 1996, 77, 2969-2981.
85. 85 Berman, P.W., Riddle, L. and Nakamura. G. et al. Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J. Virol. 1989, 63, 3489-3498.
86. 86 Kent, K.A., Rud, E. and Corcoran, T. et al. Identification of two neutralizing and eight non-neutralizing epitopes on simian immunodeficiency virus envelope using monoclonal antibodies. AIDS Res. Hum. Retrovir. 1992, 8, 1147-1151.
87. 87 Lohman, B.L., McChesney, M.B. and Miller, C.J. et al. A partially attenuated Simian Immunodeficiency Virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 1994, 68, 7021-7029.
88. 88 Marthas, M.L., Miller, C.J. and Sutjipto, S. et al. Efficacy of live-attenuated and whole inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J. Med. Primatol. 1992, 21, 99-107.
89. 89 Giavedoni, L., Ahmad, S., Jones, L. and Yilma, T. Expression of gamma interferon by simian immunodeficiency virus increases attenuation and reduces postchallenge virus load in vaccinated rhesus macaques. J. Virol. 1997, 71, 866-872.
90. 90 Denesvre, C., Le Grand, R. and Boissin-Cans, F. et al. Highly attenuated SIVmac142 is immunogenic but does not protect against SIVrnac251 challenge. AIDS Res. Hum. Retrovir. 1995, 11, 1397-1406.
91. 91 Salvato, M.S., Emau, P., Malkovsky, M., Schultz, K.T., Johnson, E. and Pauza, C.D. Cellular immune responses in rhesus macaques infected rectally with low dose simian immunodeficiency virus. J. Med. Primatol. 1994, 23, 125-130.
92. 92 Clerici, M., Clark, E.A. and Polacino, P. et al. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques. AIDS 1994, 8, 1391-1395.
93. 93 Dittmer, U., Stahl-Hennig, C. and Coulibaly, C. et al. Repeated exposure of rhesus macaques to low doses of simian immunodeficiency virus (SIV) did not protect them against the consequences of a high-dose SIV challenge. J. Gen. Virol. 1995, 76, 1307-1315.
94. 94 Geretti, A.M., Hulskotte, E.G.J., Dings, M.E.M., Van Baalen, C.A., Van Amerongen, G., Norley, S.G., Boers, P., Gruters, R.A. and Osterhaus, A.D.M.E. Virus-driven evolution of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocyte responses during primary and secondary infection of cynomolgus macaques with SIVmac32H-J5. Submitted 1997.
95. 95 Artenstein, A.W., VanCott, T.C. and Mascola, J.R. et al. Dual infection with human immunodeficiency virus type 1 of distinct envelope subtypes in humans. J. Infect. Dis. 1995, 171, 805-810.
96. 96 Petry, H., Dittmer, U. and Stahl-Hennig, C. et al. Reactivation of human immunodeficiency virus type 2 in macaques after simian immunodeficiency virus SIVmac superinfection. J. Virol. 1995, 69, 1564-1574.
97. 97 Bogers, W.M., Niphuis, H., Ten Haaft, P., Laman, J.D., Koornstra, W. and Heeney, J.L. Protection from HIV-1 envelope-bearing chimeric simian immunodeficiency virus (SHIV) in rhesus macaques infected with attenuated SIV: consequences of challenge. AIDS 1995, 9, F13-8.
98. 98 Whatmore, A.M., Cook, N., Hall, G.A., Sharpe, S., Rud, E.W. and Cranage, M.P. Repair and evolution of nef in vivo modulates simian immunodeficiency virus virulence. J. Virol. 1995, 69, 5117-5123.
99. 99 Baba, T.W., Jeong, Y.S., Pennick, D., Bronson, R., Greene, M.F. and Ruprecht, R.M. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 1995, 267, 1820-1825.
100. 100 Geretti, A.M., Hulskotte, E.G.J., Dings, M.E.M., Van Baalen, C.A., Van Amerongen, G. and Osterhaus, A.D.M.E. Simian immunodeficiency virus (SIV)-specific CD8+ cytotoxic T lymphocyte responses of naive and vaccinated cynomolgus macaques infected with SIVmac32H(J5); quantitative analysis by in vitro antigenic stimulation. Vaccine 1997, 15, 1269-1275.
101. 101 Letvin, N.L., Reimann, K.A., Yasutomi, Y., Ringler, D.J. and Yamamoto, H. The SIVmac specific cytotoxic T lymphocyte response in the acutely infected rhesus monkey. Current Topics Microbiol. Immunol. 1994, 188, 175-184.
102. 102 Letvin, N.L., Li, J., Halloran, M., Cranage, M.P., Rud, E.W. and Sodroski, J. Prior infection with a nonpathogenic chimeric simian-human immunodeficiency virus does not efficiently protect macaques against challenge with simian immunodeficiency virus. J. Virol. 1995, 69, 4569-4571.
103. 103 Miller, C.J., McChesney, M.B. and Xusheng, L. et al. Rhesus macaques previously infected with simian/human immunodeficiency virus are protected from vaginal challenge with pathogenic SIVmac239. J. Virol. 1997, 71, 1911-1921.
104. 104 Quesada-Rolander, M., Makitalo, B. and Thorstensson, R. et al. Protection against mucosal SIVsm challenge in macaques infected with a chimeric SIV that expresses HIV type 1 envelope. AIDS Res. Hum. Retrovir. 1996, 12, 993-999.
105. KU-1. Virology 1997, 234, 328-339.
106. 106 Putkonen, P., Walther, L. and Zhang, Y.J. et al. Long-term protection against SIV-induced disease in macaques vaccinated with a live attenuated HIV-2 vaccine. Nature Med. 1995, 1, 914-918.
107. 107 Putkonen, P., Makitalo, B., Bottiger, D., Biberfeld, G. and Thorstensson, R. Protection of human immunodeficiency virus type 2-exposed seronegative macaques from mucosal simian immunodeficiency virus transmission. J. Virol. 1997, 71, 4981-4984.
108. 108 Travers, K., Mboup, S. and Marlink, R. et al. Natural protection against HIV-1 infection provided by HIV-2. Science 1995, 268, 1612-1615.
109. 109 Zou, W., Lackner, A.A. and Simon, M. et al. Early cytokine and chemokine gene expression in lymph nodes of macaques infected with simian immunodeficiency virus is predictive of disease outcome and vaccine efficacy. J. Virol. 1997, 71, 1227-1236.
110. 110 Mitchell, T. and Risser, R. Interference established in mice by infection with Friend murine leukemia virus. J. Virol. 1992, 66, 5696-5702.
111. 111 Tartaglia, J., Cox, W.I. and Taylor, J. et al. Highly attenuated poxvirus vectors. AIDS Res. Hum. Retrovir. 1992, 8, 1445-1447.
112. 112 Sutter, G. and Moss, B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 1992, 89, 10847-10851.
113. 113 Meyer, H., Sutter, G. and Mayr, A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 1991, 72, 1031-1038.
114. 114 Franchini, G., Robert-Guroff, M. and Tartaglia, J. et al. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retrovir. 1995, 11, 909-920.
115. 115 Andersson, S., Makitalo, B. and Thorstensson, R. et al. Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J. Infect. Dis. 1996, 174, 977-985.
116. 116 Myagkikh, M., Alipanah, S. and Markham, P.D. et al. Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res. Hum. Retrovir. 1996, 12, 985-992.
117. 117 Biberfeld, G., Thorstensson, R. and Putkonen, P. Protection against human immunodeficiency virus type 2 and simian immunodeficiency virus in macaques vaccinated against human immunodeficiency virus type 2. AIDS Res. Hum. Retrovir. 1996, 12, 443-446.
118. 118 Abimiku, A.G., Franchini, G. and Tartaglia, J. et al. HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nature Med. 1995, 1, 321-329.
119. 119 Hu, S.-L., Abrams, K. and Barber, G.N. et al. Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160. Science 1992, 255, 456-459.
120. 120 Kent, S.J., Hu, S.L., Corey, L., Morton, W.R. and Greenberg, P.D. Detection of simian immunodeficiency virus (SIV)-specific CDS+ T cells in macaques protected from SIV challenge by prior SIV subunit vaccination. J. Virol. 1996, 70, 4941-4947.
121. 121 Hu, S.L., Polacino, P. and Stallard, V. et al. Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection. Immunol. Lett. 1996, 51, 115-119.
122. 122 Hirsch, V.M., Fuerst, T.R. and Sutter, G. et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 1996, 70, 3741-3752.
123. 123 Giavedoni, L.D., Planelles, V. and Haigwood, N.L. et al. Immune response of rhesus macaques to recombinant Simian Immunodeficiency Virus gp130 does not protect from challenge infection. J. Virol. 1993, 67, 577-583.
124. 124 Schlienger, K., Montefiori, D.C., Mancini, M., Roviere, Y., Tiollais, P. and Michel, M. Vaccine-induced neutralizing antibodies directed in part to the Simian Immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge. J. Virol. 1994, 68, 6578-6588.
125. 125 Daniel, M.D., Mazzara, G.P. and Simon, M.A. et al. High-liter immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection. AIDS Res. Hum. Retrovir. 1994, 10, 839-850.
126. 126 Stahl-Hennig, C., Coulibaly, C. and Petry, H. et al. Immunization with virion-derived glycoprotein 130 from HIV-2 or SIV protects macaques against challenge virus grown in human or simian cells or prepared ex vivo. AIDS Res. Hum. Retrovir. 1994, 10, S27-S32.
127. 127 Dittmer, U., Nisslein, T. and Bodemer, W. et al. Cellular immune response of rhesus monkeys infected with a partially attenuated nef deletion mutant of the simian immunodeficiency virus. Virology 1995, 212, 392-397.
128. 128 Gallimore, A., Cranage, M. and Cook, N. et al. Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nature Med. 1995, 1, 1167-1173.
129. 129 Yasutomi, T., Koenig, C. and Woods, R.M. et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell free simian immunodeficiency virus challenge. J. Virol. 1995, 69, 2279-2284.
130. 130 Van Baalen, C.A., Klein, M.R. and Huisman, R.C. et al. Fine-specificity of cytotoxic T lymphocytes which recognize conserved epitopes of the Gag protein of human immunodeficiency virus type 1. J. Gen. Virol. 1996, 77, 1659-1665.
131. 131 Geretti, A.M., Hulskotte, E.G.J., Dings, M.E.M., Van Baalen, C.A., Van Amerongen, G. and Osterhaus, A.D.M.E. CD8+ cytotoxic T lymphocytes of a cynomolgus macaque infected with simian immunodeficiency virus (SIV)mac32H-J5 recognize a nin amino acid epitope in SIV Gag p26. J. Gen. Virol. 1997, 78, 821-824.
132. 132 Borrow, P., Lewicki, H. and Wei, X. et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature Med. 1997, 3, 205-211.
133. 133 Harrer, E., Harrer, T. and Buchbinder, S. et al. HIV-1-specific cytotoxic T lymphocyte response in healthy, long-term nonprogressing seropositive persons. AIDS Res. Hum. Retrovir. 1994, 10, S77-S78.
134. 134 Donnelly, J.J., Ulmer, J.B., Shiver, J.W. and Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 1997, 15, 617-648.
135. 135 Ciernik, I.F., Berzofsky, J.A. and Carbone, D.P. Induction of cytotoxic T lymphocytes and anti tumor immunity with DNA vaccines expressing single T cell epitopes. J. Immunol. 1996, 156, 2369-2375.
136. 136 Kuklin, N., Daheshia, M., Karem, K., Manickan, E. and Rouse, B.T. Induction of mucosal immunity against herpes simplex virus by plasmid DNA immunization. J. Virol. 1997, 71, 3138-3145.
137. 137 Lu, S., Arthos, J. and Montefiori, D.C. et al. Simian immunodeficiency virus DNA vaccine trial in macaques. J. Virol. 1996, 70, 3978-3991.
138. 138 Letvin, N.L., Montefiori, D.C., Yasutomi, Y., Perry, H.C., Davies, M.E., Lekutis, C., Alroy, M., Freed, D.L., Lord, C.I., Handt, L.K., Liu, M.A. and Shiver, J.W. DNA vaccine-induced immunity to HIV-1 Env in rhesus monkeys. In: Abstracts of the EC-CA Workshop on FIV, SIV and SHIV Vaccination, Annecy, France, 1997, p. 40.
139. 139 Wakrim, L., Le Grand, R. and Vaslin, B. et al. Superinfection of HIV-2-preinfected macaques after rectal exposure to a primary isolate of SIVmac251. Virology 1996, 221, 260-270.
140. 140 Lu, M., Blacklow, S.C. and Kim, P.S. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nature Struct. Biol. 1995, 2, 1075-1082.
141. 141 Blacklow, S.C., Lu, M. and Kim, P.S. A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry 1995, 34, 14955-14962.
142. 142 Earl, P.L., Broder, C.C. and Long, D. et al. Native oligomeric human immunodeficiency virus type 1 envelope glycoprotein elicits diverse monoclonal antibody reactivities. J. Virol. 1994, 68, 3015-3026.
143. 143 Parren, P.W., Fisicaro, P. and Labrijn, A.F. et al. In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human immunodeficiency virus type 1 envelope. J. Virol. 1996, 70, 9046-9050.
144. 144 Poignard, P., Klasse, P.J. and Sattentau, Q.J. Antibody neutralization of HIV-1. Immunol. Today 1996, 17, 239-246.
145. 145 Fouts, T.R., Binley, J.M., Trkola, A., Robinson, J.E. and Moore, J.P. Neutralization of the human immunodeficiency virus type 1 primary isolate JR-FL by human monoclonal antibodies correlates with antibody binding to the oligomeric form of the envelope glycoprotein complex. J. Virol. 1997, 71, 2779-2785.
146. 146 Schutten, M., Andeweg, A.C., Bosch, M.L. and Osterhaus, A.D. Enhancement of infectivity of a non-syncytium inducing HIV-1 by sCD4 and by human antibodies that neutralize syncytium inducing HIV-1. Scand. J. Immunol. 1995, 41, 18-22.
147. 147 Schutten, M., Andeweg, A.C., Rimmelzwaan, G.F. and Osterhaus, A.D.M.E. Modulation of primary human immunodeficiency virus type 1 envelope glycoprotein-mediated entry by human antibodies. J. Gen. Virol. 1997, 78, 999-1006.
148. 148 Wyatt, R., Sullivan, N. and Thali, M. et al. Functional and immunologic characterization of human immunodeficiency virus type 1 envelope glycoproteins containing deletions of the major variable regions, J. Virol. 1993, 67, 4557-4565.
149. 149 Burton, D.R., Pyati, J. and Koduri, R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994, 266, 1024-1027.
150. 150 Trkola, A., Purtscher, M. and Muster, T. et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 1996, 70, 1100-1108.
151. 151 Muster, T., Steindl, F. and Purtscher, M. et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 1993, 67, 6642-6647.
152. 152 Burns, D.P. and Desrosiers, R.C. Envelope sequence variation, neutralizing antibodies, and primate lentivirus persistence. Current Topics Microbiol. Immunol. 1994, 188, 185-219.
153. 153 Girard, M. Present status of vaccination against HIV-1 infection. Int. J. Immunopharmacol. 1995, 17, 75-78.
154. 154 Koup, R.A., Safrit, J.T. and Cao. Y. et al. Temporal association of cellular immune response with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 1994, 68, 4650-4655.
155. 155 Van Baalen, C.A., Pontesilli, O., Huisman, R.C., Klein, M.R., Geretti, A.M., De Wolf, F., Miedema, F., Gruters, R.A. and Osterhaus, A.D.M.E. HIV-1 Rev and Tat specific cytotoxic T lymhpocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol., 1997, 70, 1913-1918.
156. 156 Geretti, A.M. Unpublished observation, 1997.
157. 157 Sher, A., Gazzinelli, R.T. and Oswald, I.P. et al. Role of T-cell derived cytokines in the downregulation of immune responses in parasitic and retroviral infection. Immunol. Rev. 1992, 127, 183-204.
158. 158 Brinchmann, J.E., Gaudernack, G. and Vartdal, F. CD8+ T cells inhibit HIV replication in naturally infected CD4+ T cells. Evidence for a soluble inhibitor. J. Immunol. 1990, 144, 2961-2966.
159. 159 Ahlers, J.D., Dunlop, N., Alling, D.W., Nara, P.L. and Berzofsky, J.A. Cytokine-in-adjuvant steering of the immune response phenotype to HIV-1 vaccine constructs. J. Immunol. 1997, 158, 3947-3958.